Post by Avaana Capital

In her latest article, Dr. Aastha Paliwal argues that industrial bio-engineering is entering its most consequential era yet - with data, inference, and execution layers converging simultaneously, creating a generational opportunity to redefine the economics, resilience, and competitiveness of bio-innovation. 𝗧𝗵𝗿𝗲𝗲 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗲𝗺𝗲𝗿𝗴𝗲𝗱:  🔹𝗔 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗮𝗹 𝗰𝗼𝗻𝘃𝗲𝗿𝗴𝗲𝗻𝗰𝗲 𝗼𝗳 𝗲𝗻𝗮𝗯𝗹𝗶𝗻𝗴 𝗳𝗮𝗰𝘁𝗼𝗿𝘀 𝗵𝗮𝘀 𝗲𝗺𝗲𝗿𝗴𝗲𝗱: Sequencing costs have collapsed 475,000-fold in 23 years. Automated labs and AI-driven bioreactors are significantly compressing R&D cycles, with each cycle generating data that retrains the model and accelerates the next. 🔹𝗗𝗮𝘁𝗮 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝗰𝗲 𝗿𝗲𝗺𝗮𝗶𝗻𝘀 𝘁𝗵𝗲 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗯𝗼𝘁𝘁𝗹𝗲𝗻𝗲𝗰𝗸: Predictive models continue to be trained on substrates generated under laboratory conditions that behave categorically differently at industrial biomanufacturing scale. 🔹𝗧𝗵𝗲 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆: The next frontier of bio innovation belongs to founders building proprietary data generation strategies and production-relevant biological datasets that cannot be replicated from published literature or substituted by compute capability alone. Companies like Phyx44 Labs and BacAlt are already developing globally competitive solutions shaping the future of biotech. At Avaana, we remain deeply committed to supporting this emerging opportunity and backing exceptional founders driving the next wave of transformation. Read the full article here: https://lnkd.in/dDGA2fZq Anjali Bansal | Sandeep Singhal | Vikas Verma | Shruti Srivastava | Rahul Bhapkar | Rishubh Malpani | Archit Bhargava | Shreya Bhattacharjee